$ACH News

Accendra Health Updates Capital Plans; Nets $45M From Non-Core Asset Sales And Sets CEO Succession Timeline For September

UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5

Citigroup Downgrades Accendra Health (ACH)

Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health, Inc. 2026 Q2 - Results - Earnings Call Presentation

Accendra Health Adopts Section 382 Rights Agreement To Protect Long-Term Shareholder Value By Preserving Its Net Operating Loss Carryforwards

Accendra Health Lowers FY2026 Sales Guidance from $2.550B-$2.650B to $2.450B-$2.550B vs $2.574B Est

Accendra Health’s President And CEO Edward Pesicka Plans To Retire By 2026 End

Accendra Health Q2 Preview: Low Expectations Create Opportunity

Citigroup Maintains Buy on Accendra Health, Lowers Price Target to $4.5

Accendra Health Files Prospectus For Offering $200M Mixed Shelf

Accendra Health (ACH) Price Target Increased by 28.92% to 4.27

Accendra Health, Inc. 2026 Q1 - Results - Earnings Call Presentation

Accendra Health, Inc. (ACH) Shareholder/Analyst Call Prepared Remarks Transcript

UBS Maintains Neutral on Accendra Health, Raises Price Target to $4.5

Citigroup Maintains Buy on Accendra Health, Raises Price Target to $5

Baird Maintains Outperform on Accendra Health, Raises Price Target to $6

Accendra Health Makes Progress Addressing Its Debt Load

Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript